TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Menopause care

Key Statistics

  • 5–7 yrs — Average duration of menopausal symptoms
  • 2–4× — ↑Depression rate, age 42–52
  • 70% — ↓Flushes at 12WK, NK3 antagonist

Don't-miss facts

  1. Bio-identical hormones are NOT an evidence-based "alternative" to HRT

  2. Only clonidine and NK3 antagonists are licensed for vasomotor symptoms; NK3 antagonists (fezolinetant/elinzanetant) ↓flushes up to 70% by 12 weeks but are not yet NHS-prescribable and need LFT monitoring (2–3% stop for ↑transaminases)

  3. Gabapentin only works for flushes at 900 mg/day (300 mg = no benefit); pregabalin 150 mg BD ↓flushes 71%

  4. Sertraline, duloxetine (mod-high dose), paroxetine, fluoxetine ↓tamoxifen efficacy – prefer citalopram or venlafaxine in tamoxifen users

  5. Ginseng and possibly black cohosh/milk thistle/sage are oestrogenic – caution/avoid in hormone-sensitive cancer

  6. Vitamin E, omega-3, and high-dose (≥1000 mg) turmeric all reduce tamoxifen's chemopreventive effect

  7. GSM in AI-treated breast cancer survivors: manage non-hormonally first; DHEA/low-dose vaginal estrogen only if severe and after individualised MDT discussion

  8. Trial each alternative for 8–12 weeks before stopping/switching; review prescribables at 3 & 6 months

Licensed vs off-label vasomotor drugs

Licensed: clonidine, NK3 antagonists Off-label: SSRIs/SNRIs, gabapentin, pregabalin, oxybutynin, mirtazapine

Avoid/caution with tamoxifen or hormone-sensitive cancer

Ginseng St John's wort Milk thistle Sage High-dose turmeric Vitamin E/omega-3 (high dose)

Sertraline/duloxetine/paroxetine/fluoxetine

Abbreviation Key

  • HRT — hormone replacement therapy
  • iCR — isopropanolic black cohosh
  • GSM — genitourinary syndrome of menopause
  • HA — hyaluronic acid
  • DHEA — dehydroepiandrosterone
  • FSFI — Female Sexual Functioning Index
  • AI — aromatase inhibitor
  • ER — estrogen receptor
  • CBT — cognitive behavioural therapy
  • GLP-1 — glucagon-like peptide-1 (receptor agonist)
  • SSRI — selective serotonin reuptake inhibitor
  • PARP — poly-ADP ribose polymerase
  • SNRI — selective norepinephrine reuptake inhibitor
  • ADHD — attention deficit hyperactivity disorder
  • MDT — multidisciplinary team
  • NICE — National Institute for Health and Care Excellence
  • NK3 — neurokinin 3 (receptor antagonist)

Source: Menopause care: alternatives to hormone replacement therapy. The Obstetrician & Gynaecologist 2025;27:308–320. doi:10.1111/tog.70010

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free